United Kingdom

People: Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

9:00pm BST
Change (% chg)

$0.33 (+5.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Peters, Richard 

Dr. Richard Peters, M.D., Ph.D. has been appointed as President, Chief Executive Officer, Director of the Company effective August 21, 2017. He has served as our President and Chief Executive Officer and a member of our board of directors since February 2017. Prior to joining us, Dr. Peters served in various capacities at Sanofi Genzyme, a global pharmaceutical company, since 2008, including as Senior Vice President, Head of Global Rare Diseases Business Unit since January 2015, Vice President, Strategy Development Officer, U.S. Rare Disease Unit from May 2014 to December 2014, Vice President, Division Medical Officer, Global Oncology Division from 2011 to May 2014, and Vice President, Head of Global and U.S. Medical Affairs, Hematology and Transplant from 2008 to 2011. Prior to Sanofi Genzyme, Dr. Peters held medical affairs roles at Onyx Pharmaceuticals, Inc. and Amgen Inc., both pharmaceutical companies, and was a co-founder and Chief Executive Officer of Mednav, Inc., a healthcare information technology company. Dr. Peters has also served on the faculty at Harvard Medical School/Massachusetts General Hospital. Dr. Peters holds an M.D. and a Ph.D. in pharmacology from the Medical University of South Carolina and a B.S. from the College of Charleston. We believe that Dr. Peters is qualified to serve on our board of directors because of his extensive leadership experience in oncology and specialty care, his extensive knowledge of our industry and his medical oncology expertise.

Basic Compensation

Total Annual Compensation, USD 2,052,390
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,725,830
Fiscal Year Total, USD 3,778,220

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --